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Single-Molecule Counting of High-Sensitivity Troponin I in Patients
Referred for Diagnostic Angiography: Results From the CASABLANCA
(Catheter Sampled Blood Archive in Cardiovascular Diseases) Study
Cian P. McCarthy, MB, BCh, BAO; Nasrien E. Ibrahim, MD; Asya Lyass, PhD, Yiwei Li, MS; Hanna K. Gaggin, MD, MPH; Mandy L. Simon,
DNP, FNP-BC, Renata Mukai, BA; Parul Gandhi, MD; Noreen Kelly, MD; Shweta R. Motiwala, MD; Roland R. J. van Kimmenade, MD, PhD;
Joseph M. Massaro, PhD; Ralph B. D’Agostino Sr PhD; James L. Januzzi Jr MD
Background-—The meaning of high-sensitivity troponin I (hsTnI) concentrations in patients without acute myocardial infarction (MI)
requires clarity. We hypothesized that among patients referred for diagnostic coronary angiography without acute MI, hsTnI
concentrations would correlate with prevalent coronary artery disease (CAD) and predict incident cardiovascular events and
mortality.
Methods and Results-—We measured hsTnI using a single-molecule counting assay (99th percentile, 6 ng/L) in samples from 991
patients obtained at the time of angiography. Concentrations of hsTnI were assessed relative to the severity of CAD and prognosis
during mean follow-up of 3.7 years. Median hsTnI concentration was 4.19 ng/L; 38% of patients had hsTnI concentrations ≥99th
percentile. Across increasing hsTnI quartiles, patients had higher prevalence of angiographic CAD; in multivariate models, hsTnI
≥99th percentile independently predicted obstructive CAD (odds ratio: 2.57; P<0.001) and incident MI (hazard ratio [HR]: 2.68;
P<0.001), cardiovascular death (HR: 2.29; P=0.001), and all-cause death (HR: 1.84; P=0.004). In those with >70% coronary
stenosis, hsTnI ≥99th percentile independently predicted incident MI (HR: 1.87; P=0.01), cardiovascular mortality (HR: 2.74;
P=0.001), and the composite end point of MI and all-cause death (HR: 2.06; P<0.001). In participants with coronary stenosis <70%,
hsTnI ≥99th percentile even more strongly predicted incident MI (HR: 8.41; P<0.001), cardiovascular mortality (HR: 3.60; P=0.03),
and the composite end point of MI and all-cause death (HR: 3.62; P<0.001).
Conclusions-—In a large prospective cohort of patients who were free of prevalent MI and undergoing diagnostic coronary
angiography, hsTnI concentrations were associated with higher prevalence of CAD and predicted incident MI, cardiovascular death,
and all-cause death.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identiﬁer: NCT00842868. ( J Am Heart Assoc. 2018;7:
e007975. DOI: 10.1161/JAHA.117.007975.)
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C ardiovascular disease is a major modern health concern;it is projected that by 2030, >23.3 million people
globally will die annually from acute myocardial infarction
(MI), stroke, and other cardiovascular diseases.1 Patients with
coronary artery disease (CAD) are naturally at higher risk of
developing cardiovascular events compared with the general
population; however, even among patients with CAD, inci-
dence of cardiovascular events can vary substantially. In
patients with stable CAD enrolled in the REACH (Reduction of
Atherothrombosis for Continued Health) registry, for example,
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the annual mortality rate ranged from 0.63% in patients with
nonobstructive CAD to 3.8% in higher risk patients.2 Conse-
quently, efforts to improve risk stratiﬁcation, permitting
appropriate intervention for each individual, are merited.
In recent years, biomarkers have been identiﬁed as
important tools for prognostication in patients with CAD
beyond that with conventional risk factors, and most data
focused on the value of biomarkers for those with acute
syndromes such as MI.3–6 The most widely studied biomark-
ers for evaluation of acute complications of CAD are cardiac
troponins I and T. Recent reﬁnements in assay technology
have led to the development of highly sensitive assays for
measurement of cardiac troponin. Although they have advan-
tages over conventional troponin methods for earlier and
more rapid identiﬁcation of acute MI, it is of interest that high-
sensitivity troponin (hsTn) assays are also able to detect
circulating concentrations of the biomarker in patients not
previously thought to have acute myonecrosis; such increased
sensitivity leads to reclassiﬁcation from unstable angina to
acute MI in a signiﬁcant percentage of patients, as well as
detection of myocardial injury or necrosis in those not
previously considered to have an acute coronary syndrome.
Nevertheless, elevations in troponin may not be exclusively
explained by myonecrosis.7 This detection of hsTn elevation in
those without MI has led to some consternation about
ambiguity regarding the meaning of such a situation and has
led to the increased use of terms such as myocardial “injury”
to explain this ﬁnding; better deﬁnition of the description of
patients without MI that have higher hsTn would be of use.
Beyond its diagnostic use, hsTn is also recognized as a
prognostic biomarker in various cardiac diseases.8,9 It
remains unclear, however, how this prognostic value varies
based on presence and severity of CAD; few studies have
examined the prognostic utility of hsTn in patients with
varying magnitude of atherosclerotic disease,10–12 in part
because of a lack of well-deﬁned coronary anatomy in these
trials.
Given these open questions, we examined the diagnostic
and prognostic utility of hsTnI in 991 patients without acute
MI referred for diagnostic coronary angiography for various
indications who were enrolled in the CASABLANCA (Catheter
Sampled Blood Archive in Cardiovascular Diseases) study
(ClinicalTrials.gov identiﬁer NCT00842868).13 We hypothe-
sized that hsTnI concentrations would correlate with preva-
lent CAD and predict incident cardiovascular events and
mortality in patients with obstructive and nonobstructive
CAD.
Methods
Study Population
All study procedures were approved by the Partners Health-
care institutional review board and consistent with the
Declaration of Helsinki. The data, analytic methods, and
study materials will not be made available to other
researchers for purposes of reproducing the results or
replicating the procedure. The CASABLANCA study was a
prospective, single-center, investigator-initiated, observational
cohort study undertaken at Massachusetts General Hospital
in Boston.13 Over a 3-year period between September 2008
and November 2011, 1251 participants undergoing coronary
and peripheral angiography with or without intervention were
enrolled. End point adjudication was performed using the
guidance of the Third Universal Deﬁnition of Myocardial
Infarction, with local fourth-generation cardiac troponin T as
the biomarker standard for diagnosis of MI; for the purposes
of the adjudication, the 99th percentile cardiac troponin T
concentration of 0.01 ng/mL was utilized. After excluding
patients who underwent peripheral angiography only and
patients with acute MI, our ﬁnal study cohort for this analysis
consisted of 991 patients (Figure 1).
After informed consent was obtained, demographics,
clinical characteristics, reason for referral for angiography,
and angiographic results (based on the ﬁnal report from the
procedure) were noted at the time of the procedure. As
previously reported, patients were mainly referred for evalu-
ation of CAD (Table S1).13
Biomarker Testing
Immediately before angiography angiographic procedures,
15 mL of blood was obtained through a centrally placed
vascular access sheath. All samples were promptly cen-
trifuged for 10 minutes. Samples were aliquoted on ice and
then immediately placed in a 80°C freezer for permanent
storage.
Clinical Perspective
What Is New?
• In patients undergoing diagnostic coronary angiography,
high-sensitivity troponin I concentrations were associated
with higher prevalence of coronary artery disease and
independently predicted cardiovascular events in patients
with obstructive and nonobstructive coronary artery
disease.
What Are the Clinical Implications?
• These data highlight the diagnostic and prognostic utility of
high-sensitivity troponin I in patients with coronary artery
disease for identifying patients who may beneﬁt from more
aggressive medical therapy to reduce atherothrombotic risk.
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Using aliquots that had undergone their ﬁrst thaw,
concentrations of hsTnI were measured using a single-
molecule counting assay (SMC troponin I; Singulex) performed
on an Erenna platform. This very highly sensitive assay has a
limit of detection of 0.5 ng/L and a 99th percentile reference
limit of 6 ng/L in apparently healthy individuals.
Follow-up and Outcomes
Incident MI, heart failure (HF), cardiovascular death, and all-
cause mortality were recorded over a median follow-up period
of 1486 days (quartile 1: 1203 days; quartile 3: 1577 days).
The mean follow-up period was 1338 days (SD: 367 days). A
detailed deﬁnition of each end point for CASABLANCA has
been described previously.13 For identiﬁcation of clinical end
points during follow-up, bioinformatics-assisted review of
medical records and phone follow-up with patients and/or
primary care physicians were performed. Each clinical end
point was adjudicated by a panel of investigators. The Social
Security Death Index and/or postings of death announce-
ments were used to conﬁrm status. No patients were lost to
follow-up.
For the purposes of the present analysis, obstructive CAD
was deﬁned as ≥70% stenosis in at least 1 vessel, and
nonobstructive CAD was deﬁned as stenosis >0% but <70%.
Statistical Analysis
Baseline characteristics between those with hsTnl >99th
versus <99th percentile were compared using the v2 or Fisher
exact test for dichotomous variables, the Cochran–Mantel–
Haenszel test for categorical variables, and the t test or
Kruskal–Wallis test for continuous variables. The following
covariates were included in all cross-sectional and prognostic
analyses in addition to hsTnl: age, sex, heart rate, systolic blood
pressure, diastolic blood pressure, atrial ﬁbrillation or ﬂutter,
hypertension, CAD, chronic obstructive pulmonary disease,
diabetes mellitus, chronic kidney disease, medications used
(angiotensin-converting enzyme inhibitor or angiotensin recep-
tor blocker, beta blockers, calcium channel blocker, aldos-
terone antagonist, loop diuretics, nitrates), sodium, glomerular
ﬁltration rate, glucose, hemoglobin, myeloperoxidase, NT-
proBNP (N-terminal pro-B-type natriuretic peptide), and
cystatin C.
Figure 1. Study ﬂow. Following removal of those without coronary angiography and those with prevalent
myocardial infarction, the study sample comprised 991 patients. Angio indicates angiography;
CASABLANCA, Catheter Sampled Blood Archive in Cardiovascular Diseases Study; MI, myocardial
infarction.
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Logistic regression was ﬁrst used to assess the cross-
sectional relationship between obstructive CAD and the above
set of individual predictors. Covariates signiﬁcant at 0.10 level
were then included into a stepwise logistic regression, with
hsTnl, age, and sex forced into the model.
Cox proportional hazards models were used to predict the
following outcomes in all patients, in the subset of patients
with obstructive CAD, and in the subset of patients with
nonobstructive CAD, using the set of covariates listed above:
incident MI, incident HF, cardiovascular death, all-cause
death, and the combined outcomes of incident MI, HF, and
all-cause death; incident MI and cardiovascular death; and
incident MI and all-cause death. Again, covariates signiﬁcant
at 0.10 level were then included in a stepwise Cox propor-
tional hazards model, with hsTnl, age, and sex forced in. The
analyses that included MI as an outcome were additionally
adjusted for previous MI; all analyses that included HF as an
outcome were additionally adjusted for previous HF.
Kaplan–Meier curves were compared using the log-rank
test. In all statistical analyses, a 2-tailed P value of <0.05 was
considered statistically signiﬁcant. All analyses were per-
formed using the SAS version 9.4 (SAS Institute).
Results
Baseline Characteristics
The median hsTnI concentration in the study sample was
4.19 ng/L (Table S2). Elevation in hsTnI ≥99th percentile was
observed in 375 patients (38%). The most common reason for
referral for coronary angiography was stable angina (44.9%).
Other reasons for referral included chest pain (20.3%),
unstable angina (13.5%), preoperative evaluation (13.2%),
arrhythmia evaluation (6.7%), and transplant evaluation (1.2%).
Baseline characteristics of study participants, dichoto-
mized as a function of elevated hsTnI ≥99th percentile, are
detailed in Table 1. Those with versus without elevated hsTnI
concentration were more likely to be older and typically had
more complex medical histories; they were more likely to have
prior history of diabetes mellitus, chronic kidney disease,
peripheral arterial disease, HF, prior MI, atrial ﬁbrillation or
ﬂutter, lower left ventricular ejection fraction, and higher right
ventricular systolic pressure. In addition, those with elevated
hsTnI typically had higher concentrations of other prognostic
biomarkers (Table 1).
hsTnI and Coronary Angiography Results
Of the 991 patients included in this study, 619 patients were
found to have obstructive CAD, 226 patients had nonobstruc-
tive CAD, and the remaining 146 patients either had no
evidence of coronary disease or were missing information.
Patients with an hsTnI ≥99th percentile had a higher degree
and number of stenotic coronary lesions (Table 2). For
example, 21.5% of patients without prevalent MI and hsTnI
concentration ≥6 ng/L had severe (≥70% stenosis) 3-vessel
disease versus 14.7% without prevalent MI and hsTnI
concentration <6 ng/L (P=0.006).
In multivariate analysis, dichotomized hsTnI (≥99th per-
centile) independently predicted obstructive CAD (odds ratio:
2.57; 95% conﬁdence interval [CI], 1.73–3.80; P<0.001;
Tables S3–S6). In receiver operating characteristic analyses,
hsTnI had an area under the curve of 0.61 for obstructive CAD
(95% CI, 0.58–0.65). A hsTnI concentration ≥6 ng/L had
sensitivity of 44%, speciﬁcity of 72%, positive predictive value
of 72%, and negative predictive value of 43% for obstructive
CAD. An hsTnI concentration below the limit of detection had
a negative predictive value of 37% for obstructive CAD
(Table S7). Assessed as a continuous variable, log-trans-
formed hsTnI also independently predicted obstructive CAD
(odds ratio: 1.43, P<0.001), yielding a C statistic of 0.82 (95%
CI, 0.78–0.85).
Prognostic Outcomes
Over a median follow-up period of 1486 days, there were 147
MIs, 238 HF exacerbations, 113 cardiovascular deaths, and
149 all-cause deaths (Table S44). In Kaplan–Meier survival
analyses, time to incident MI (Figure 2A) was substantially
shorter and incidence was higher in those with hsTnI ≥99th
percentile; the survival curves diverged early, and by end of
follow-up, cumulative incidence of MI was 27% versus 9% in
those with elevated versus low hsTnI (log-rank P<0.001).
Similar patterns were seen relative to cardiovascular death
(log-rank P<0.001; Figure 2B), all-cause death (log-rank
P<0.001; Figure 2C), the composite end point of MI and all-
cause death (log-rank P<0.001; Figure 2D), and the compos-
ite end point of MI and cardiovascular death (log-rank
P<0.001; Figure 2E).
In fully adjusted multivariate analysis (Table 3), in all
participants, hsTnI ≥99th percentile independently predicted
incident MI (hazard ratio [HR]: 2.68; 95% CI, 1.86–3.85;
P<0.001), incident HF (HR: 1.60; 95% CI, 1.21–2.13; P=0.01),
cardiovascular death (HR: 2.29; 95% CI, 1.40–3.75; P=0.001),
and all-cause death (HR: 1.84; 95% CI, 1.22–2.78; P=0.004).
In addition, an elevated hsTnI concentration independently
predicted composite end points of incident MI, HF, and all-
cause mortality (HR: 1.62; P<0.001); incident MI and cardio-
vascular death (HR: 2.22; P<0.001), and incident MI and all-
cause death (HR: 2.13; P<0.001; Tables S8–S21). In a
subanalysis of prognostic outcomes among men and women,
hsTnI ≥99th percentile more strongly predicted all-cause
death in women (HR: 5.83; P<0.001) compared with men (HR:
1.48; P=0.10) and incident HF in men (HR: 1.71; P<0.001)
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Table 1. Baseline Characteristics of Study Participants as a Function of hsTnI 99th Percentile
Characteristics hsTnI <99th Percentile (n=616) hsTnI ≥99th Percentile (n=375) P Value
Demographic
Age, y, meanSD 65.0310.79 68.9811.83 <0.001
Male sex, % 69.97 75.20 0.08
Race, % 0.97
White 93.67 93.60
Black 1.95 2.93
Asian/Pacific 0.81 1.60
Hispanic 2.11 1.87
Vital signs, meanSD
Heart rate, beats/min 67.913.0 70.714.2 0.002
Systolic blood pressure, mm Hg 135.721.2 138.124.4 0.12
Diastolic blood pressure, mm Hg 72.511.0 73.112.1 0.41
Medical history, %
Smoker 12.5 14.0 0.50
Atrial fibrillation/flutter 16.6 26.9 <0.001
Hypertension 71.3 77.3 0.04
CAD 50.0 53.9 0.24
Prior MI 21.4 28.0 0.02
HF 15.1 31.7 <0.001
Peripheral artery disease 14.5 23.5 <0.001
COPD 16.4 18.9 0.31
Diabetes mellitus type I/II 22.2 30.9 0.002
CVA/TIA 9.6 11.2 0.41
CKD 6.5 20.5 <0.001
Renal replacement therapy 1.1 6.7 <0.001
Prior angioplasty 9.6 11.7 0.28
Prior stent 27.9 27.5 0.88
Prior CABG 16.1 24.3 0.001
Medications, %
ACEI/ARB 50.5 58.6 0.01
Beta blocker 72.6 68.2 0.14
Aldosterone antagonist 3.6 5.6 0.13
Loop diuretics 14.7 32.6 <0.001
Nitrates 19.1 18.5 0.80
CCB 22.5 26.5 0.15
Statin 70.4 72.2 0.55
Aspirin 76. 7 71.9 0.09
Warfarin 13.5 21.1 0.002
P2Y12 inhibitor 21.2 21.4 0.96
Echocardiography, meanSD
LVEF, % 59.813.4 50.517.6 <0.001
RSVP 37.710.0 45.011.6 <0.001
Continued
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compared with women (HR: 1.36; P=0.34). Similarly, hsTn
≥99th percentile predicted incident MI (HR: 2.60; P<0.001 in
men; HR: 2.61; P=0.01 in women) and cardiovascular death
(HR: 2.28; P=0.004 in men; HR: 2.21; P=0.07 in women;
Tables S22–S29).
In an effort to better understand the prognostic meaning of
hsTnI concentrations in those with obstructive versus nonob-
structive CAD, subanalyses were undertaken by partitioning
patients based on their angiographic results (Table 3). In
patients with ≥70% coronary stenosis (n=619), hsTnI ≥99th
percentile independently predicted incident MI (HR: 1.87;
P=0.01; Figures S1 and S2), cardiovascular mortality (HR:
2.74;P=0.001), and the composite end point ofMI and all-cause
death (HR: 2.06; P<0.001). In patients with nonobstructive CAD
(n=226), hsTnI ≥99th percentile even more strongly predicted
incident MI (HR: 8.41; P<0.001; Figures S2 and S3), cardiovas-
cular mortality (HR: 3.60; P=0.03), and the composite end point
ofMI and all-cause death (HR: 3.62; P<0.001; Tables S30–S43).
Discussion
In a large prospective cohort study of patients without
prevalent MI undergoing diagnostic coronary angiography, we
found that elevations in hsTnI were common, were associated
with a higher prevalence of obstructive CAD, and indepen-
dently predicted numerous cardiovascular events including
incident MI, incident HF, cardiovascular death, and all-cause
death. Risk associated with elevated hsTnI appeared early and
was sustained across follow-up. Furthermore, we found that
elevated hsTnI remained prognostic for adverse outcome
regardless of degree of coronary obstruction and appeared
even more prognostic for those without obstructive CAD.
Table 1. Continued
Characteristics hsTnI <99th Percentile (n=616) hsTnI ≥99th Percentile (n=375) P Value
Laboratory measures, meanSD
Sodium, mmol/L 139.43.1 139.53.1 0.75
Blood urea nitrogen, mg/dL 19.08.0 24.012.5 <0.001
Creatinine, mg/dL 1.140.72 1.551.47 <0.001
Total cholesterol, mg/dL 152. 941.2 146.345.8 0.06
LDL cholesterol, mg/dL 83.432.7 79.336.7 0.16
Glycohemoglobin, % 6.351.60 6.641.23 0.14
Glucose, mg/dL 111.438.5 117.441.8 0.05
Hb, g/L 13.41.6 13.01.8 <0.001
Baseline biomarkers
MPO, pmol/L, median (IQR) 391.2 (307.0–532.0) 455.8 (330.0–610.9) <0.001
Troponin I, pg/mL, median (IQR) 4.1 (2.6–6.4) 28.7 (15.1–85.6) <0.001
NT-proBNP, pg/mL, median (IQR) 167.0 (71.0–462.0) 1088.0 (336.0–2789.0) <0.001
Cystatin C, mg/L, median (IQR) 0.8 (0.7–0.9) 0.9 (0.7–1.2) <0.001
ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCB, calcium channel
blocker; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; Hb, hemoglobin; HF, heart failure; hsTnI, high-sensitivity troponin I;
IQR, interquartile range; LDL, low-density lipoprotein; LVEF, left ventricular ejection fraction; MI, myocardial infarction; MPO, myeloperoxidase; NT-proBNP, N-terminal pro-B-type natriuretic
peptide; RVSP, right ventricular systolic pressure; TIA, transient ischemic attack.
Table 2. Presence and Severity of CAD as a Function of hsTnI
Concentrations Dichotomized Around the 99th Percentile
Value
Angiography Results
hsTnI <99th
Percentile
(n=616), %
hsTnI ≥99th
Percentile
(n=375), % P Value
≥30% coronary stenosis
in ≥2 vessels
54.9 69.1 <0.001
≥30% coronary stenosis
in ≥3 vessels
38.1 53.8 <0.001
≥50% coronary stenosis
in ≥2 vessels
44.3 55.9 <0.001
≥50% coronary stenosis
in ≥3 vessels
24.1 35.8 <0.001
≥70% coronary stenosis
in ≥2 vessels
32.7 42.7 0.002
≥70% coronary stenosis
in ≥3 vessels
14.7 21.5 0.006
Among patients without acute myocardial infarction, an elevated hsTnI was associated
with more prevalent and extensive coronary stenosis. CAD indicates coronary artery
disease; hsTnI, high-sensitivity troponin I.
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Our observations that hsTn concentrations correlated with
the number and degree of stenotic coronary lesions and that
elevated hsTn is an independent predictor of obstructive CAD
lend important understanding of how such hsTn values should
be interpreted clinically. In a prior case–control study involving
904 patients with stable CAD and 412 patients with chest pain
but without signiﬁcant CAD on coronary angiogram, Ndrepepa
et al demonstrated hsTnT concentrations correlated with an
increasing number of stenotic coronary lesions and with 30%
higher likelihood of the presence of CAD.14 Such case–control
methodsmay underestimate the predictive value of hsTn in part
because of the inability to easily mimic pretest probability of a
patient population referred for diagnostic coronary angiogra-
phy. Our results generated with a substantially higher sensi-
tivity hsTnI method in a population with higher pretest
probability suggest that concentrations of hsTnI even more
strongly predict presence of obstructive CAD. Lending context
to our ﬁndings, among a lower risk population of patients with
Figure 2. Cumulative event curves over a follow-up period of 1440 days in patients with or without elevated hsTnI ≥6 ng/L for (A) incident
MI, (B) incident cardiovascular death, (C) all-cause death, (D) composite of MI and all-cause death, and (E) composite of MI and cardiovascular
death. hsTnI indicates high-sensitivity cardiac troponin I; MI, myocardial infarction.
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acute chest pain, we previously showed that very low hsTnI
concentrations (measured with another assay) excluded
prevalent CAD with higher negative predictive value.15 Taken
together, our results suggest that among patients with lower
pretest probability, very low concentrations of hsTn may
conﬁdently exclude CAD, whereas in those with higher pretest
probability, the greater value of hsTn may identify obstructive
CAD. These results complement those of Twerenbold et al,
who found that logical ordering and interpretation of hsTn
concentrations improved accuracy of diagnostic coronary
angiography.16 Given the present release of hsTn methods in
the United States, it is imperative that clinicians understand the
impact of pretest probability when ordering and interpreting
hsTn results.
Notably, we found hsTn concentrations ≥99th percentile to
be a robust independent predictor of all-cause mortality,
cardiovascular death, incident MI, and incident HF. Interest-
ingly, in patients with nonobstructive CAD, we found that an
elevated hsTnI concentration was a powerful predictor of
incident MI (HR: 8.41; P<0.001) and cardiovascular mortality
(HR: 3.60; P=0.03). This is a cohort that is often overlooked in
clinical practice when discovered to have nonobstructive
disease; however, over a 1486-day follow-up period, our study
found that the cumulative incidence of MI was actually higher
in patients with nonobstructive disease and elevated hsTnI
≥99th percentile (23%) compared with patients with obstruc-
tive CAD and an hsTnI concentration <99th percentile (12%);
the incidence of incident MI in patients with obstructive CAD
and hsTnI ≥99th percentile was 30%. Further studies should
evaluate the utility of hsTnI to trigger application of more
aggressive medical therapies to reduce atherothrombotic risk
(eg, directed application of higher dose statin therapy, PCSK9
[proprotein convertase subtilisin/kexin type 9] inhibitor
therapy, direct oral anticoagulant use) in this cohort.
Although this study is one of the ﬁrst of its kind to explore
diagnostic and prognostic meanings of a novel single-
molecule hsTnI method, it has limitations. We excluded those
patients with prevalent MI at the time of enrollment (judged
using cardiac troponin T at its 99th percentile); however, it is
possible that some patients would have been recognized as
having MI if adjudicated with the hsTnI under study in the
present analysis. This issue of equipoise is an inevitable
consequence of higher sensitivity, and it is fair to expect such
limitations to affect any study examining hsTn methods in
patients with ischemic heart disease. Concentrations of hsTnI
were measured at a single point in time at the time of
angiography and may not reﬂect levels at future time periods.
It is necessary to note the hsTnI assay used in this analysis is
time-consuming compared with processing of conventional
troponin assays; more efﬁcient versions of such highly
sensitive methods would be needed to translate these results
for efﬁcient clinical use. Our results need further validation
and should not be extrapolated to the general population
without suspected CAD because these patients were not
included in our study. Whether aggressive treatment strate-
gies in patients with an elevated hsTn concentration would
modify their risk of future cardiovascular events remains
unknown and requires further investigation.
With assays of increasing sensitivity coming into more
widespread use, clinicians face detection of abnormal values
in patients not thought to have acute MI. This has led to
increased use of nonspeciﬁc terms such as myocardial injury
that lack therapeutic imperatives. Our results suggest even
Table 3. Prognostic Outcomes as a Function of hsTnI ≥99th
Percentile in All Participants and in Those With Presence of
Obstructive CAD (Deﬁned as ≥70% Stenosis)
Outcome HR 95% CI P Value
Incident MI
All participants (N=991) 2.68 1.86–3.85 <0.001
Obstructive CAD (n=619) 1.87 1.16–3.00 0.01
Nonobstructive CAD (N=226) 8.41 2.77–25.5 <0.001
Incident HF
All participants (N=991) 1.60 1.21–2.13 0.001
Obstructive CAD (n=619) 1.17 0.76–1.80 0.46
Nonobstructive CAD (n=226) 1.61 0.85–3.06 0.14
Cardiovascular death
All participants (N=991) 2.29 1.40–3.75 0.001
Obstructive CAD (n=619) 2.74 1.48–5.06 0.001
Nonobstructive CAD (n=226) 3.60 1.15–11.3 0.03
All-cause death
All participants (N=991) 1.84 1.22–2.78 0.004
Obstructive CAD (n=619) 2.06 1.26–3.37 0.004
Nonobstructive CAD (n=226) 2.25 0.83–6.12 0.11
Incident MI/HF/all-cause death
All participants (N=991) 1.62 1.26–2.08 <0.001
Obstructive CAD (n=619) 1.71 1.25–2.33 <0.001
Nonobstructive CAD (n=226) 1.60 0.88–2.90 0.12
Incident MI/cardiovascular death
All participants (N=991) 2.22 1.60–3.08 <0.001
Obstructive CAD (n=619) 2.06 1.40–3.05 <0.001
Nonobstructive CAD (n=226) 4.70 2.17–10.18 <0.001
Incident MI/all-cause death
All participants (N=991) 2.13 1.56–2.90 <0.001
Obstructive CAD (n=619) 2.06 1.42–2.98 <0.001
Nonobstructive CAD (n=226) 3.62 1.78–7.37 <0.001
CAD indicates coronary artery disease; CI, conﬁdence interval; HF, heart failure; HR,
hazard ratio; hsTnI, high-sensitivity troponin I; MI, myocardial infarction.
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slight elevation in hsTnI concentrations predicted the pres-
ence of obstructive CAD and independently predicted major
cardiovascular events. Our results add novel and substantial
clinical context to hsTnI concentrations in a commonly
encountered patient population (those sent for angiography)
while setting the stage for analyses of how hsTn may be
leveraged in clinical trials of therapeutic intervention for such
patients.
Conclusions
HsTnI is a powerful predictor of the presence of CAD in patients
sent for angiography not thought to have acute MI. In addition,
hsTnI predicts incident cardiovascular events in patients with
either obstructive or nonobstructive CAD. Our results will help
to clarify the meaning of elevated hsTn in patients without MI.
Further studies should evaluate the utility of hsTnI to trigger
application of more aggressive medical therapies to reduce
atherothrombotic risk (eg, more aggressive lipid lowering, use
of direct oral anticoagulants) in this cohort.
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